SRR1421093
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.426
- COAGULATION+0.301
- INFLAMMATORY_RESPONSE+0.290
- APICAL_SURFACE+0.270
- MYOGENESIS+0.260
- ALLOGRAFT_REJECTION+0.190
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.184
- PANCREAS_BETA_CELLS+0.181
- ANGIOGENESIS+0.173
- SPERMATOGENESIS+0.119
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.612
- MYC_TARGETS_V1-0.570
- UNFOLDED_PROTEIN_RESPONSE-0.557
- MYC_TARGETS_V2-0.542
- PROTEIN_SECRETION-0.501
- DNA_REPAIR-0.499
- MTORC1_SIGNALING-0.489
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.431
- PI3K_AKT_MTOR_SIGNALING-0.345
- ADIPOGENESIS-0.335
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1337431 | GTEX | — | 0.972 |
| 2 | SRR1389348 | GTEX | — | 0.966 |
| 3 | SRR1341057 | GTEX | — | 0.965 |
| 4 | SRR1440246 | GTEX | — | 0.964 |
| 5 | SRR1475803 | GTEX | — | 0.962 |
| 6 | SRR1485167 | GTEX | — | 0.962 |
| 7 | SRR1416096 | GTEX | — | 0.958 |
| 8 | SRR1322419 | GTEX | — | 0.956 |
| 9 | SRR658188 | GTEX | — | 0.956 |
| 10 | SRR1343197 | GTEX | — | 0.955 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.426 | Remibrutinib | — uncovered |
| COAGULATION | 0.301 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.184 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.181 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.173 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.119 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.116 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.103 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.095 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.090 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.089 | Inavolisib | — uncovered |
| COMPLEMENT | 0.025 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.018 | Inavolisib | — uncovered |